Nurix Therapeutics, Inc. NRIX Zelebrudomide (NX-2127) — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s zelebrudomide (nx-2127) — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s zelebrudomide (NX-2127) — R&D?
- Nurix Therapeutics, Inc. (NRIX) reported zelebrudomide (NX-2127) — R&D of $1.91M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s zelebrudomide (NX-2127) — R&D changed year-over-year?
- Nurix Therapeutics, Inc.'s zelebrudomide (NX-2127) — R&D increased by 72.3% year-over-year, from $1.11M to $1.91M.
- What does zelebrudomide (NX-2127) — R&D mean?
- This metric represents the total direct costs incurred for the research, clinical development, and pre-commercialization activities specifically associated with the Zelebrudomide (NX-2127) therapeutic candidate. It captures the investment intensity required to advance this targeted protein degrader through its clinical trial phases and regulatory milestones. Monitoring this spend provides insight into the company's capital allocation strategy and the prioritization of its pipeline assets.